{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:14:01Z","timestamp":1772831641873,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1111\/1469-0691.12440","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T20:34:43Z","timestamp":1383597283000},"page":"698-705","source":"Crossref","is-referenced-by-count":95,"title":["Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland"],"prefix":"10.1016","volume":"20","author":[{"given":"C.","family":"Orasch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Garbino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schrenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zimmerli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"M\u00fchlethaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pfyffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ruef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zbinden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Calandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12440_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/380637","article-title":"Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991\u20132000","volume":"38","author":"Marchetti","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12440_bib2","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12440_bib3","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1128\/JCM.02117-09","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion","volume":"48","author":"Pfaller","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1111\/1469-0691.12440_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1128\/AAC.01079-10","article-title":"Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008\u20132009","volume":"55","author":"Pfaller","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12440_bib5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ajic.2009.12.012","article-title":"Secular trends of candidemia in a tertiary care hospital","volume":"38","author":"Sampaio Camargo","year":"2010","journal-title":"Am J Infect Control"},{"key":"10.1111\/1469-0691.12440_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drup.2010.09.002","article-title":"Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods","volume":"13","author":"Pfaller","year":"2010","journal-title":"Drug Resist Updat"},{"key":"10.1111\/1469-0691.12440_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.diagmicrobio.2011.03.002","article-title":"Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria","volume":"70","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/1469-0691.12440_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2011.01.004","article-title":"Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria","volume":"14","author":"Pfaller","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1111\/1469-0691.12440_bib9","series-title":"Manual of Clinical Microbiology","first-page":"1184","article-title":"Candida, Cryptococcus, and other yeasts of medical importance","author":"Warren","year":"2008"},{"key":"10.1111\/1469-0691.12440_bib10","series-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, in Approved standard M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1111\/1469-0691.12440_bib11","series-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, in 3rd informal Supplement, M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1111\/1469-0691.12440_bib12","series-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth International Supplement. CLSI document M27-4","first-page":"32","author":"CLSI","year":"2012"},{"key":"10.1111\/1469-0691.12440_bib13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12440_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/jhin.2001.1131","article-title":"Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use","volume":"50","author":"Hope","year":"2002","journal-title":"J Hosp Infect"},{"key":"10.1111\/1469-0691.12440_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1471-2334-10-312","article-title":"Secular trend in candidemia and the use of fluconazole in Finland, 2004\u20132007","volume":"10","author":"Poikonen","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1111\/1469-0691.12440_bib16","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1128\/AAC.00081-09","article-title":"Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing","volume":"53","author":"Cuesta","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12440_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/CMR.19.2.435-447.2006","article-title":"Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing","volume":"19","author":"Pfaller","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/1469-0691.12440_bib18","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00296-07","article-title":"Correlation of the MIC and dose\/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia","volume":"51","author":"Rodriguez-Tudela","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12440_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/1469-0691.12440_bib20","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1128\/JCM.43.9.4434-4440.2005","article-title":"Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility","volume":"43","author":"Arendrup","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/1469-0691.12440_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijantimicag.2011.02.016","article-title":"Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008\u20132009)","volume":"38","author":"Pfaller","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/1469-0691.12440_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.eimc.2010.12.003","article-title":"[Candidemias: multicentre analysis in 16 hospitals in Andalusia (Spain)]","volume":"29","author":"Rodriguez-Hernandez","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1111\/1469-0691.12440_bib23","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1111\/j.1439-0507.2011.02027.x","article-title":"Epidemiology and management of candidaemia\u2013a retrospective, multicentre study in five hospitals in the UK","volume":"54","author":"Chalmers","year":"2011","journal-title":"Mycoses"},{"key":"10.1111\/1469-0691.12440_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3109\/13693780903410386","article-title":"Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea","volume":"48","author":"Jung","year":"2010","journal-title":"Med Mycol"},{"key":"10.1111\/1469-0691.12440_bib25","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/JCM.00937-08","article-title":"Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study","volume":"46","author":"Gonzalez","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1111\/1469-0691.12440_bib26","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1128\/JCM.02363-09","article-title":"Antifungal susceptibility testing of Candida isolates from the Candida surveillance study","volume":"48","author":"Lyon","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1111\/1469-0691.12440_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/1469-0691.12440_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/JCM.01811-10","article-title":"National surveillance of fungemia in Denmark (2004 to 2009)","volume":"49","author":"Arendrup","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1111\/1469-0691.12440_bib29","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1111\/j.1439-0507.2011.02165.x","article-title":"Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study","volume":"55","author":"Schmalreck","year":"2012","journal-title":"Mycoses"},{"key":"10.1111\/1469-0691.12440_bib30","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/jac\/dks019","article-title":"Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey","volume":"67","author":"Peman","year":"2012","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14611629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14611629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T22:22:59Z","timestamp":1539210179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14611629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1198743X14611629"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12440","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}